avapro has been researched along with Metabolic Syndrome in 25 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following a 1-week screening withdrawal period, 482 patients (mean age 59 ± 10 years, 53% men) bearing a SBP at least 140 mmHg and/or DBP at least 90 mmHg plus metabolic syndrome (ATP-III criteria) were randomly allocated to a fixed-dose combination of zofenopril 30 mg plus hydrochlorothiazide 12." | 9.22 | Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd ( Borghi, C; Napoli, C; Omboni, S, 2016) |
| "Telmisartan seemed to improve glycaemic and lipid control and metabolic parameters of the metabolic syndrome better than irbesartan." | 9.12 | Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA, 2007) |
| "Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0." | 6.76 | Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. ( Bartlett, M; Dole, WP; Hanefeld, M; Jung, T; Krone, W; Meyer, HF; Prescott, MF; Rajman, I; Yeh, CM, 2011) |
| " Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile." | 5.42 | Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome. ( Hirooka, Y; Nishihara, M; Sunagawa, K, 2015) |
| " Following a 1-week screening withdrawal period, 482 patients (mean age 59 ± 10 years, 53% men) bearing a SBP at least 140 mmHg and/or DBP at least 90 mmHg plus metabolic syndrome (ATP-III criteria) were randomly allocated to a fixed-dose combination of zofenopril 30 mg plus hydrochlorothiazide 12." | 5.22 | Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd ( Borghi, C; Napoli, C; Omboni, S, 2016) |
| "This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468 patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP] > or =100 mm Hg) at high cardiovascular risk." | 5.14 | Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. ( Franklin, SS; Neutel, JM, 2010) |
| "Telmisartan seemed to improve glycaemic and lipid control and metabolic parameters of the metabolic syndrome better than irbesartan." | 5.12 | Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA, 2007) |
| " In this study, thirteen-week-old spontaneously hypertensive (SHR)/NDmcr-cp rats, representing a genetic model of metabolic syndrome, were treated daily with placebo, irbesartan (30 mg/kg), valsartan (10 mg/kg), or pioglitazone (10 mg/kg) for 4 weeks." | 3.77 | Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. ( Jin, D; Miyazaki, M; Takai, S, 2011) |
| "In this study, we evaluated whether a combination of an angiotensin-converting enzyme (ACE) inhibitor, benazepril (B), with an angiotensin type I receptor antagonist (AT1RA), irbesartan (I), is as effective or more than drugs as monotherapy in controlling renal damage in obese Zucker rats (OZR), a model of metabolic syndrome." | 3.72 | ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats. ( Cao, G; DeRosa, G; Pagano, P; Piorno, P; Toblli, JE, 2004) |
| "Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0." | 2.76 | Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. ( Bartlett, M; Dole, WP; Hanefeld, M; Jung, T; Krone, W; Meyer, HF; Prescott, MF; Rajman, I; Yeh, CM, 2011) |
| "The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction." | 2.71 | Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. ( Cheema, FA; Khan, BV; Khan-Merchant, N; Menon, RG; Mir, MQ; Parthasarathy, S; Sola, S, 2005) |
| "Thirty percent had type 2 diabetes mellitus, 46% had metabolic syndrome, and baseline blood pressure was 154." | 2.71 | The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Neutel, JM; Ofili, EO; Saunders, E; Sowers, JR; Weber, MA, 2005) |
| "Hypertension is an important risk factor for cardiovascular disease (CVD), particularly in patients with comorbid obesity, diabetes, metabolic disease, or end-organ damage." | 2.44 | The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. ( Ruilope, LM; Segura, J, 2008) |
| "The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value." | 2.43 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. ( Pershadsingh, HA, 2006) |
| " Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile." | 1.42 | Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome. ( Hirooka, Y; Nishihara, M; Sunagawa, K, 2015) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| "The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality." | 1.34 | Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. ( Bramlage, P; Kintscher, U; Paar, WD; Thoenes, M; Unger, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, MA | 1 |
| Amin, EF | 1 |
| Ibrahim, SA | 1 |
| Abdelzaher, WY | 1 |
| Abdelrahman, AM | 1 |
| Nishihara, M | 1 |
| Hirooka, Y | 1 |
| Sunagawa, K | 1 |
| Napoli, C | 1 |
| Omboni, S | 1 |
| Borghi, C | 1 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
| de las Heras, N | 1 |
| Martín-Fernández, B | 1 |
| Miana, M | 1 |
| Ballesteros, S | 1 |
| Oubiña, MP | 1 |
| López-Farré, AJ | 1 |
| Cachofeiro, V | 1 |
| Lahera, V | 1 |
| Russell, JC | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Proctor, SD | 1 |
| Muñoz, MC | 2 |
| Giani, JF | 1 |
| Dominici, FP | 1 |
| Turyn, D | 1 |
| Toblli, JE | 3 |
| Parhofer, KG | 2 |
| Birkeland, KI | 1 |
| DeFronzo, R | 1 |
| Del Prato, S | 1 |
| Bhaumik, A | 1 |
| Ptaszynska, A | 1 |
| Krone, W | 1 |
| Hanefeld, M | 1 |
| Meyer, HF | 1 |
| Jung, T | 1 |
| Bartlett, M | 1 |
| Yeh, CM | 1 |
| Rajman, I | 1 |
| Prescott, MF | 1 |
| Dole, WP | 1 |
| Franklin, SS | 1 |
| Neutel, JM | 3 |
| Simonenko, VB | 1 |
| Medvedev, IN | 1 |
| Tolmachev, VV | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Miyazaki, M | 1 |
| Tong, XL | 1 |
| Lian, FM | 1 |
| Zhou, Q | 1 |
| Xu, LP | 1 |
| Ji, HY | 1 |
| Xu, GC | 1 |
| Hu, YH | 1 |
| Zhao, LH | 1 |
| Xia, L | 1 |
| Wang, J | 1 |
| Chen, XY | 1 |
| Chan, MH | 1 |
| Zhang, LL | 1 |
| Gao, W | 1 |
| Zhen, Z | 1 |
| Zhou, SP | 1 |
| Chang, B | 1 |
| DeRosa, G | 2 |
| Cao, G | 2 |
| Piorno, P | 1 |
| Pagano, P | 1 |
| Sola, S | 1 |
| Mir, MQ | 1 |
| Cheema, FA | 1 |
| Khan-Merchant, N | 1 |
| Menon, RG | 1 |
| Parthasarathy, S | 1 |
| Khan, BV | 1 |
| Saunders, E | 2 |
| Bakris, GL | 2 |
| Cushman, WC | 2 |
| Ferdinand, KC | 2 |
| Ofili, EO | 2 |
| Sowers, JR | 2 |
| Weber, MA | 2 |
| Pershadsingh, HA | 1 |
| Rakugi, H | 1 |
| Ogiwara, T | 1 |
| Ando, H | 1 |
| Fujimura, A | 1 |
| Negro, R | 1 |
| Formoso, G | 1 |
| Hassan, H | 1 |
| Kintscher, U | 1 |
| Bramlage, P | 1 |
| Paar, WD | 1 |
| Thoenes, M | 1 |
| Unger, T | 1 |
| Fogari, E | 1 |
| D'Angelo, A | 1 |
| Cicero, AF | 1 |
| Salvadeo, SA | 1 |
| Ragonesi, PD | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Fassi, R | 1 |
| Fogari, R | 1 |
| Münzel, F | 1 |
| Krekler, M | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome[NCT00110422] | Phase 4 | 400 participants | Interventional | 2005-11-30 | Completed | ||
| Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial[NCT03788759] | Phase 2/Phase 3 | 48 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for avapro and Metabolic Syndrome
| Article | Year |
|---|---|
The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Causality; Cer | 2008 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Tri | 2006 |
[Renin-angiotensin system].
Topics: Adipocytes; Amides; Angiotensin-Converting Enzyme 2; Antihypertensive Agents; Biphenyl Compounds; Fu | 2006 |
10 trials available for avapro and Metabolic Syndrome
| Article | Year |
|---|---|
Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Synd
Topics: Aged; Biphenyl Compounds; Captopril; Female; Humans; Hydrochlorothiazide; Irbesartan; Male; Metaboli | 2016 |
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, T | 2010 |
Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Cardiovascular Dise | 2011 |
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Body Mas | 2010 |
Prospective multicenter clinical trial of Chinese herbal formula JZQG (Jiangzhuoqinggan) for hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2013 |
Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Biomarkers; Biphenyl Compounds; Brachi | 2005 |
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2005 |
The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.
Topics: Adiponectin; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; | 2006 |
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Topics: Adiponectin; Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2007 |
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2007 |
12 other studies available for avapro and Metabolic Syndrome
| Article | Year |
|---|---|
Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats.
Topics: Acetates; Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds | 2014 |
Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome.
Topics: Animals; Antihypertensive Agents; Antioxidants; Biphenyl Compounds; Blood Pressure; Heart Rate; Hype | 2015 |
The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance.
Topics: Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Aorta; B | 2009 |
Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiovascular Diseases; Infla | 2009 |
Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blo | 2009 |
[Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Female; | 2010 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 2011 |
ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2006 |
[PPARgamma-activating properties of angiotensin receptor blockers].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimi | 2006 |
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Topics: Abdominal Fat; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Comp | 2007 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |